Gap Med02: We do not have the capability to provide a safe and effective pharmacy for exploration missions.
Last Published:  07/30/21 01:05:31 PM (Central)
Responsible Element: Exploration Medical Capability (ExMC)
Status: Closed
Closure Rationale

This gap has been consolidated with the PK/PD concern and elevated to an inclusive Pharm Risk. As such, it will no longer be kept as a gap within the Medical Risk.

Please see new Pharm risk and associated gaps.

Closure Documentation:
No Closure Documentation Available
Description

Initial State:
A major concern of exploration missions is that the duration may exceed the expiration date of a medication.  The purpose of this gap is to identify a strategy to ensure that medications needed during an exploration mission are available, safe, and effective.

Approach:
Projects will be conducted to explore avenues that will:
    1. Improve understanding of current drug usage and stability during spaceflight and what medications to manifest during an exploration mission.
    2. Understand any changes in bioavailability (pharmacokinetics and pharmacodynamics) that will impact the clinical effectiveness of medications selected.
    3. Optimize the usable lifespan of a medication by providing storage recommendations within the vehicle environment.
    4. Ensure the availability of medications by exploring the possibility of drug pre-position and/or resupply (based on the DRM) and the technology behind in-vehicle production.

Target for Closure
A recommendation of an exploration pharmacy and policies that support the operational concept for each DRM.
Mappings
Risk Risk of Adverse Health Outcomes and Decrements in Performance Due to Medical Conditions that occur in Mission, as well as Long Term Health Outcomes Due to Mission Exposures
You are here! Gap Med02: We do not have the capability to provide a safe and effective pharmacy for exploration missions.
Completed

Multi-Disciplinary Research Plans

Documentation:
No Documentation Available